<SEC-DOCUMENT>0001193125-26-288752.txt : 20260629
<SEC-HEADER>0001193125-26-288752.hdr.sgml : 20260629
<ACCEPTANCE-DATETIME>20260629172227
ACCESSION NUMBER:		0001193125-26-288752
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260629
FILED AS OF DATE:		20260629
DATE AS OF CHANGE:		20260629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41842
		FILM NUMBER:		261136997

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		PROVINCE COUNTRY:   	I0
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		PROVINCE COUNTRY:   	I0
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d110874d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of June 2026 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-41842</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Abivax SA </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation
of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">7-11</FONT> boulevard Haussmann </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>75009 Paris, France </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+33
(0) 1 53 83 08 41 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive
offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Positive Topline Results from Part 2 of Phase 3 ABTECT <FONT STYLE="white-space:nowrap">44-Week</FONT>
Maintenance Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2026, Abivax SA (the &#8220;Registrant&#8221; or the &#8220;Company&#8221;) announced positive topline results from
Part 2 of its Phase 3 ABTECT <FONT STYLE="white-space:nowrap">44-week</FONT> maintenance trial evaluating obefazimod, the Company&#8217;s potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> oral <FONT
STYLE="white-space:nowrap">miR-124</FONT> enhancer, in moderate to severely active ulcerative colitis (&#8220;UC&#8221;). Part 2 of the Phase 3 maintenance trial enrolled patients who either did not achieve clinical response following induction
treatment or who experienced disease relapse during the <FONT STYLE="white-space:nowrap">re-randomized</FONT> maintenance trial (Part 1), expanding both the efficacy and safety results in a more refractory patient population than the registrational
maintenance cohort. The additional safety results generated through Part 2 expand the Phase 3 maintenance database and provide important context for interpreting the safety findings reported following the Maintenance Part 1 readout. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among patients who failed to achieve clinical response after 8 weeks of induction, continued treatment with obefazimod resulted in clinically meaningful rates
of clinical, endoscopic, and combined histologic-endoscopic endpoints at Week 44. Patients treated continuously with 50 mg obefazimod demonstrated the strongest outcomes across all endpoints, including clinical remission (37.2%), clinical response
(61.5%), endoscopic improvement (48.0%), Histologic-Endoscopic Mucosal Improvement (&#8220;HEMI&#8221;) (44.6%), and endoscopic remission (34.5%). These findings suggest that a clinically meaningful proportion of patients who do not initially
respond may still derive substantial benefit from longer treatment exposure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="5"><B>Part 2 Induction Non-Responders &#8211; Exploratory Endpoints</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>25 mg</B><br>(N=81)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50 mg</B><br>(N=148)</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical Remission</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B></B>23.5%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">37.2%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical Response</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B></B>50.6%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">61.5%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Endoscopic Improvement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B></B>28.4%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">48.0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>HEMI</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B></B>23.5%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">44.6%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Endoscopic Remission</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B></B>22.2%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">34.5%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among patients who relapsed during Part 1 of the maintenance trial, <FONT STYLE="white-space:nowrap">re-treatment</FONT> with
50 mg obefazimod resulted in meaningful rates of clinical remission, clinical response, endoscopic improvement, HEMI and endoscopic remission by Week 44. Patients who achieved clinical response with obefazimod during induction and relapsed after
being <FONT STYLE="white-space:nowrap">re-randomized</FONT> to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod and achieved clinical response and remission rates of 69.7% and 45.0%, respectively, while
patients who relapsed on 25 mg and escalated to 50 mg achieved clinical response and clinical remission rates of 66.7% and 45.5%, respectively. These findings demonstrate the potential for obefazimod to
<FONT STYLE="white-space:nowrap">re-establish</FONT> disease control following relapse and support a flexible maintenance treatment strategy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="5"><B>Part 1 Relapsers &#8211; Exploratory Endpoints</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo&nbsp;</B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT><B></B><B>&nbsp;50&nbsp;mg</B><br><B></B>(N=109)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>25&nbsp;mg&nbsp;</B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT><B></B><B>&nbsp;50&nbsp;mg</B><br><B></B>(N=33)<B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50&nbsp;mg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50&nbsp;mg</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical Remission</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45.0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45.5%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Clinical Response</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">69.7%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">66.7%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Endoscopic Improvement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">54.1%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45.5%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>HEMI</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">47.7%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">39.4%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Endoscopic Remission</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">32.1%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">24.2%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Part 2, four total <FONT STYLE="white-space:nowrap">non-melanoma</FONT> skin cancers (&#8220;NMSC&#8221;) events were
reported, two in the 25 mg arm and two in the 50 mg arm which all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies. There were
also two <FONT STYLE="white-space:nowrap">non-NMSC</FONT> malignancies reported in the 50 mg arm, both deemed unrelated to obefazimod by the study investigators. The results are summarized below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Summary Safety Events, n (%)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Obefazimod&nbsp;25&nbsp;mg</B><br><B>N=186</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Obefazimod&nbsp;50&nbsp;mg</B><br><B>N=447*</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any treatment-emergent adverse event (&#8220;TEAE&#8221;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">132&nbsp;(71.0%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">307&nbsp;(68.7%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEAE leading to study drug discontinuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">21 (11.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">27 (6.0%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious TEAE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">16 (8.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">23 (5.1%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Death <FONT STYLE="white-space:nowrap">(Non-Treatment</FONT> Related)<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pregnancy<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.2%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious/severe (Grade &#8805;3) infections and opportunistic infections<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 (2.7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 (1.1%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malignancies (excluding NMSC)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (0.4%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NMSC<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (1.1%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (0.4%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acute pancreatitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.5%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.2%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiac abnormalities suggestive of cardiac fibrosis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">One death occurred in the 25 mg arm and was assessed by the investigator as unrelated to obefazimod. The
suspected cause was pulmonary embolism in a 65+ patient with multiple <FONT STYLE="white-space:nowrap">pre-existing</FONT> thromboembolic risk factors, including prior pulmonary embolism, and recent prolonged immobility. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Both pregnancies are currently ongoing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Serious/severe (grade &#8805;3) infections and opportunistic infections: 25 mg = Appendicitis, Bartonellosis,
Cytomegalovirus gastrointestinal infection, Peritonsillar abscess, Sepsis; 50 mg (induction <FONT STYLE="white-space:nowrap">non-responder)</FONT> = Clostridium difficile infection, pilonidal disease, Urethritis gonococcal; 50 mg Open Label (Part 1
relapsers = Appendicitis (Part 1 50 mg), Septic arthritis staphylococcal (Part 1 placebo). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Part 1 relapsers previous on placebo: One case of Myoproliferative Neoplasm and one Prostate Cancer.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Two cases of Basal Cell Carcinoma (25 mg | 50 mg) and two cases of Squamous Cell Carcinoma (25 mg | 50 mg).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes combined induction <FONT STYLE="white-space:nowrap">non-responders</FONT> on 50 mg in Part 2 (N=251)
and Part 1 relapsers (N=196) who entered Part 2. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Malignancy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Excluding</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NMSC)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Exposure&nbsp;to<BR>Obefazimod</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>&#8194;Age&#8194;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Thiopurine<BR>History</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Prior&nbsp;Advanced<BR>Therapies</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Other Prior UC<BR>Treatment</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Medical&nbsp;History<BR>of Cancer</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;"><B>Summary</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50&#8194;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">mg&#8194;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Myeloproliferative Neoplasm (MPN)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">7.4&nbsp;months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">40+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(adalimumab, infliximab)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">mesalazine</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Thrombocythemia since 2023. Had elevated platelets at baseline (909,000 per microliter)</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined not related to study drug by
investigator</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Prostate Cancer</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">3.4 months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">55+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">azathioprine</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(infliximab, vedolizumab)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">prednisolone, mesalazine, budesonide</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Limited adenocarcinoma of the prostate CT2 CN0 M0; Gleason score 7B</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined not related to study drug by
investigator</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>NMSC</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Exposure&nbsp;to<BR>Obefazimod</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Thiopurine<BR>History</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Prior&nbsp;Advanced<BR>Therapies</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Other Prior UC<BR>Treatment</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>Medical&nbsp;History<BR>of Skin Cancer</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;"><B>Summary</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;">50&#8194; mg&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Basal Cell Carcinoma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">10.4&nbsp;months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">40+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">azathioprine</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vedolizumab, infliximab, ustekinumab</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">mesalazine, prednisone</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Thiopurine use and failure of 3 prior advanced therapies</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined probably related to study drug by investigator</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Squamous Cell Carcinoma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">4.6 months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">55+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">azathioprine</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">adalimumab, vedolizumab</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">budesonide</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Yes</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prior history of squamous cell carcinoma and history of multiple skin lesions</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined not related to study drug by
investigator</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt;">25&#8194; mg&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Basal Cell Carcinoma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">8.1 months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">50+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">azathioprine</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">None</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000;">budesonide, sulfasalazine, mesalazine, prednisone, metranidazole, sodium butyrate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Age 50+, prior thiopurine
history</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined unlikely related to study drug by
investigator</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Squamous Cell Carcinoma</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">8.3 months</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">75+</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">No</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">adalimumab, vedolizumab</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">prednisone, mesalamine</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">Yes</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Age 75+ and prior history of 2x Basal</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">cell carcinoma</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determined probably related to study drug by investigator</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The post-hoc analyses below are presented progressively, from the combined Phase 2 and Phase 3 UC programs to the Phase 3
maintenance dataset (Part 1 and Part 2), and then to the Part 2 maintenance dataset, to illustrate how increasing cumulative patient-years (&#8220;PYs&#8221;) strengthens the overall safety assessment. Because NMSCs and malignancies excluding NMSCs
are uncommon events, incidence-rate estimates become more precise as cumulative exposure increases. The Company believes the Phase 3 maintenance data should be interpreted using the totality of the exposure-adjusted evidence, together with patient
characteristics and representative published UC epidemiologic reference </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ranges. The results in the tables below demonstrate that the exposure-adjusted incidence rate (&#8220;EAIR&#8221;) in the combined all active (25 mg and 50 mg) treatment arms for both NMSCs and
malignancies excluding NMSCs are within the UC background reference range based on published UC studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" COLSPAN="11" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Malignancies (Excluding NMSC) &#8211; EAIR Analysis</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"><B>Analysis Set</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Placebo</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IR/100
PY</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>25
mg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IR/100 PY</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>50
mg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IR/100 PY</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All
Active</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IR/100 PY</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference Range</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Based
on</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Published UC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Studies</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Integrated
UC Program</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Phase 2 + Phase 3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.64</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.35</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.30 &#8211; 0.70</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 3
Maintenance</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Part 1 + Part 2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.91</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.56</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.30 &#8211; 0.70</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part 2
Only</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>&#8212;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.00</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.69</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.48</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.30 &#8211; 0.70</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: IR = incidence rate </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" COLSPAN="11" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>NMSC &#8211; EAIR Analysis</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"><B>Analysis Set</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Placebo</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>IR/100
PY<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>25
mg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>IR/100 PY<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>50
mg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>IR/100 PY<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All
Active</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B>IR/100 PY<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference Range</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Based
on</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Published UC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Studies</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Integrated
UC Program</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Phase 2 + Phase 3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.46</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.53</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.64</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.59</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.70 &#8211; 1.40</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 3
Maintenance</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Part 1 + Part 2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.68</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>1.09</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>1.37</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>1.26</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.70 &#8211; 1.40</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part 2
Only</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>&#8212;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>1.52</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.69</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;"><B>0.95</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt;">0.70 &#8211; 1.40</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: IR = incidence rate </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
overall safety results observed in Part 2 were consistent with those previously observed in the broader obefazimod clinical development program. No new safety pattern emerged with the additional cumulative exposure provided by Part 2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Path Forward </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes the
foregoing Part 2 results expand the integrated clinical dataset supporting the planned New Drug Application (&#8220;NDA&#8221;) for obefazimod in UC. The Company believes it remains on track to submit its NDA to the U.S. Food and Drug Administration
in the fourth quarter of 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Next Anticipated Key Milestones </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">September&nbsp;21, 2026 &#8211; Half-year 2026 financial results </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fourth Quarter 2026 &#8211; Planned NDA submission for obefazimod in UC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Mid-2027</FONT> &#8211; Topline results from the Phase 2b <FONT
STYLE="white-space:nowrap">ENHANCE-CD</FONT> induction trial evaluating obefazimod in Crohn&#8217;s disease </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Press Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing the foregoing results is furnished as Exhibit 99.1 to this Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;6-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> excluding Exhibit 99.1, shall be deemed to be incorporated by reference into the
Registrant&#8217;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File Nos. <FONT STYLE="white-space:nowrap">333-283336</FONT> and <FONT STYLE="white-space:nowrap">333-288884)</FONT> and Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (File Nos. <FONT STYLE="white-space:nowrap">333-286069</FONT> and <FONT STYLE="white-space:nowrap">333-294544)</FONT> and to be part thereof from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit Index </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d110874dex991.htm">Press Release, dated June&nbsp;29, 2026 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> contains forward-looking statements, forecasts and estimates, including those relating to the
Company&#8217;s business and financial objectives. Words such as &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;potential&#8221; and variations of such words and similar expressions are intended to identify forward-looking statements. These
forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod and obefazimod&#8217;s potential to redefine treatment expectations, the expected timing for completion of the Phase 2b <FONT
STYLE="white-space:nowrap">ENHANCE-CD</FONT> induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, the timing for reporting
Abivax&#8217;s half year 2026 financial results, and other statements that are not historical fact. Although the Registrant&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of the Registrant, that could cause actual results and
developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company
with the French Autorit&eacute; des March&eacute;s Financiers pursuant to its legal obligations including its universal registration document (<I>Document d&#8217;Enregistrement Universel</I>) and in its Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> filed with the U.S. Securities and Exchange Commission on March&nbsp;23, 2026 under the caption &#8220;Risk Factors.&#8221; These risks, contingencies and uncertainties include, among other things, the
uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding
labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company&#8217;s foreseeable and unforeseeable operating expenses and capital
expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the
assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this Report. Readers are cautioned not to place
undue reliance on these forward-looking statements. The Registrant disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by
law. Information about pharmaceutical products (including products currently in development) that is included in this Report is not intended to constitute an advertisement. This Report is for information purposes only, and the information contained
herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has
no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change
without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Abivax SA</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June 29, 2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc de Garidel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marc de Garidel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d110874dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:17pt; font-family:Verdana" ALIGN="center"><FONT COLOR="#614dd1"><B>Abivax Reports Positive ABTECT Maintenance </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Verdana" ALIGN="center"><FONT COLOR="#614dd1"><B>Part 2 Results for Obefazimod, Demonstrating </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Verdana" ALIGN="center"><FONT COLOR="#614dd1"><B>Meaningful Clinical Benefit in Refractory Ulcerative </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Verdana" ALIGN="center"><FONT COLOR="#614dd1"><B>Colitis Patients and Strengthening the Phase 3 </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Verdana" ALIGN="center"><FONT COLOR="#614dd1"><B>Maintenance Safety Database </B></FONT></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><I>Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis (&#8220;UC&#8221;)
population, with 37.2% of induction <FONT STYLE="white-space:nowrap">non-responders</FONT> achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatment</I> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><I>Dose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT
Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease control over time</I> </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><I>Across the integrated Phase 2 and Phase 3 UC program (1,704 patient-years of exposure), exposure-adjusted incidence
rates (&#8220;EAIRs&#8221;) for malignancies excluding <FONT STYLE="white-space:nowrap">non-melanoma</FONT> skin cancer (&#8220;NMSC&#8221;) were 0.35 and 0.64 events per 100 patient-years (&#8220;PYs&#8221;), and for NMSC were 0.59 and 0.64 events
per 100 PYs in the <FONT STYLE="white-space:nowrap">all-active</FONT> combined (50 mg + 25 mg) and 50 mg cohorts, respectively, all consistent with expected UC background rates</I> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><I>In ABTECT Maintenance Part 2, EAIRs for malignancies excluding NMSC were 0.48 and 0.69 events per 100 PYs, and for
NMSC were 0.95 and 0.69 events per 100 PYs, in the <FONT STYLE="white-space:nowrap">all-active</FONT> combined and 50 mg cohorts, respectively, all consistent with expected UC background rates</I> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><I>Abivax to host a conference call and webcast today at 4:30 p.m. EDT (10:30 p.m. CEST) to discuss the results</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>PARIS, France &#8211; June</B><B></B><B>&nbsp;29, 2026 &#8211; 10:05 pm CEST</B> &#8211; <FONT
STYLE="font-family:Verdana; font-size:11pt" COLOR="#0000ff"><U>Abivax SA</U></FONT><FONT STYLE="font-family:Verdana"> (Euronext Paris: FR0012333284 &#8211; ABVX / Nasdaq: ABVX) (&#8220;Abivax&#8221; or the &#8220;Company&#8221;), a clinical-stage
biotechnology company focused on developing therapeutics that harness the body&#8217;s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced topline results from ABTECT
Maintenance Part 2, the supplemental portion of its Phase 3 UC maintenance program evaluating obefazimod, its investigational oral <FONT STYLE="white-space:nowrap">miR-124</FONT> enhancer, in adults with moderately to severely active UC.
</FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">
Part 2 of the Phase 3 Maintenance trial enrolled patients who either did not achieve clinical response following induction treatment or who experienced disease relapse during the <FONT
STYLE="white-space:nowrap">re-randomized</FONT> maintenance trial (Part 1), expanding both the efficacy and safety results in a more refractory patient population than the registrational maintenance cohort. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">The additional safety results generated through Part 2 expand the Phase 3 maintenance database and provide important context for interpreting the safety findings
reported following the Maintenance Part 1 readout. The integrated <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses presented today include the new Part 2 results, the combined Phase 3 maintenance program, and the broader Phase 2 and Phase 3
clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Marc de Garidel, MBA, Chief Executive Officer of</B><B></B><B>&nbsp;Abivax, said:</B><I> &#8220;The results from ABTECT
Maintenance Part 2 represent an important milestone in the clinical development of obefazimod, demonstrating meaningful clinical benefit in patients with highly refractory ulcerative colitis while substantially expanding our long-term safety
database. Together with the unprecedented efficacy results from the ABTECT Phase 3 program, these findings build a comprehensive body of evidence supporting the potential of obefazimod to address significant unmet needs across a broad spectrum of
patients living with ulcerative colitis.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><I>&#8220;The expanded cumulative safety data further strengthens our confidence in the long-term safety profile of
obefazimod and reinforces the favorable benefit-risk profile for our program as we prepare for our planned NDA submission later this year. We believe this growing body of evidence positions obefazimod, if approved, to become a paradigm defining
treatment option for patients living with ulcerative colitis.&#8221; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Clinically meaningful efficacy results observed in induction <FONT
STYLE="white-space:nowrap">non-responders</FONT> following additional obefazimod exposure </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Among patients who failed to achieve clinical response after 8
weeks of induction, continued treatment with obefazimod resulted in clinically meaningful rates of clinical, endoscopic, and combined histologic-endoscopic endpoints at Week 44. Patients treated continuously with 50 mg obefazimod demonstrated the
strongest outcomes across all endpoints, including clinical remission (37.2%), clinical response (61.5%), endoscopic improvement (48.0%), Histologic-Endoscopic Mucosal Improvement (&#8220;HEMI&#8221;) (44.6%), and endoscopic remission (34.5%). These
findings suggest that a meaningful proportion of patients who do not initially respond may still derive substantial benefit from longer treatment exposure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR BGCOLOR="#a6a6a6" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>Part 2 Induction <FONT STYLE="white-space:nowrap">Non-Responders</FONT> &#8211; Exploratory
Endpoints</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B>&#8195;25&nbsp;mg&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B></B>(N=81)<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B>&#8195;50&nbsp;mg&#8195;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B></B>(N=148)<B></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Clinical Remission</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">23.5%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">37.2%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Clinical Response</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">50.6%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">61.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Endoscopic Improvement</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">28.4%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">48.0%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>HEMI</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">23.5%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">44.6%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Endoscopic Remission</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">22.2%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">34.5%</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Obefazimod recaptured clinical and endoscopic outcomes in patients who relapsed during maintenance treatment
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Among patients who relapsed during Maintenance Part 1, <FONT STYLE="white-space:nowrap">re-treatment</FONT> with 50 mg obefazimod resulted in clinically
meaningful rates of clinical remission, clinical response, endoscopic improvement, HEMI and endoscopic remission by Week 44. Patients who achieved clinical response with obefazimod during induction and relapsed after being <FONT
STYLE="white-space:nowrap">re-randomized</FONT> to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod and achieved clinical response and remission rates of 69.7% and 45.0%, respectively, while patients who
relapsed on 25 mg and escalated to 50 mg achieved clinical response and remission rates of 66.7% and 45.5%, respectively. These findings demonstrate the potential for obefazimod to <FONT STYLE="white-space:nowrap">re-establish</FONT> disease control
following relapse and support a flexible maintenance treatment strategy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR BGCOLOR="#a6a6a6" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>Part 1 Relapsers &#8211; Exploratory Endpoints</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">&#8195;Placebo-&gt;50&nbsp;mg&#8195;</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B></B>(N=109)<B></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9; padding-right:2pt;">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B><FONT STYLE="white-space:nowrap">&#8195;25&nbsp;mg-&gt;50&nbsp;mg&#8195;</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Verdana" ALIGN="center"><B></B>(N=33)<B></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>50 mg</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>50 mg</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Clinical Remission</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">45.0%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">45.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Clinical Response</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">69.7%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">66.7%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Endoscopic Improvement</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">54.1%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">45.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>HEMI</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">47.7%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">39.4%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #d9d9d9; padding-left:8pt;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Verdana"><B>Endoscopic Remission</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">32.1%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #d9d9d9; BORDER-TOP:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #d9d9d9; BORDER-RIGHT:1px solid #d9d9d9; BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; ">24.2%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Part 2 meaningfully expanded the cumulative safety dataset, increasing confidence in obefazimod&#8217;s long-term safety profile
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">The <FONT STYLE="white-space:nowrap">post-hoc</FONT> analyses below are presented progressively, from the combined Phase 2 and Phase 3 UC programs to the
Phase 3 maintenance dataset (Part 1 + Part 2), and then to the Part 2 maintenance dataset, to illustrate how increasing cumulative patient-years strengthens the overall safety assessment. In Part 2, four total NMSC events were reported, two in the
25 mg arm and two in the 50 mg arm, which all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies. There were also two <FONT
STYLE="white-space:nowrap">non-NMSC</FONT> malignancies reported in the 50 mg arm, both deemed unrelated to obefazimod by the study investigators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Because NMSCs
and malignancies excluding NMSCs are uncommon events, incidence-rate estimates become more precise as cumulative exposure increases. The ABTECT Maintenance data should be interpreted using the totality of the exposure-adjusted evidence, together
with patient characteristics and representative published UC epidemiologic reference ranges. The results in the tables below demonstrate that the exposure-adjusted incidence rate in the combined all active (25 mg + 50 mg) treatment arms for both
NMSCs and malignancies excluding NMSCs are within the UC background reference range based on published UC studies. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="11"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>Malignancies (Excluding NMSC) &#8211; EAIR Analysis</B></FONT></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#e8e8e8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050; BORDER-TOP:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #00b050; BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR BGCOLOR="#e8e8e8" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>Analysis Set</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>Placebo<BR></B>IR/100&nbsp;PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>25 mg<BR></B>IR/100&nbsp;PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>50 mg<BR></B>IR/100&nbsp;PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>All Active<BR></B>IR/100&nbsp;PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>Expected UC<BR>Background<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP></B></FONT></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#c1f0c7">
<TD HEIGHT="8" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR BGCOLOR="#c1f0c7" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Integrated UC
Program<BR>(Phase 2 + Phase 3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.00</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.00</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.64</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.35</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.30 &#8211; 0.70</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Phase 3
Maintenance<BR>(Part 1 + Part 2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.00</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.00</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #d9d9d9;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #d9d9d9;"><FONT STYLE="font-family:Verdana; "><B>0.91</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.56</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.30 &#8211; 0.70</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #d9d9d9;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Part 2 Only</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>&#8212;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>0.00</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>0.69</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1.50pt solid #00b050;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #00b050;"><FONT STYLE="font-family:Verdana; "><B>0.48</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #00b050;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1.50pt solid #00b050; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.30 &#8211; 0.70</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:24pt; font-family:Verdana">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="11"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>NMSC &#8211; EAIR Analysis</B></FONT></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#e8e8e8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050; BORDER-TOP:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1.50pt solid #00b050; BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR BGCOLOR="#e8e8e8" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>Analysis Set</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>Placebo<BR></B>IR/100 PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>25 mg<BR></B>IR/100 PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>50 mg<BR></B>IR/100 PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>All Active<BR></B>IR/100 PY<B></B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>Expected UC<BR>Background<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP></B></FONT></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#c1f0c7">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR BGCOLOR="#c1f0c7" STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Integrated UC
Program<BR>(Phase 2 + Phase 3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.46</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.53</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.64</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.59</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.70 &#8211; 1.40</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Phase 3
Maintenance</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>(Part 1 + Part 2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>0.68</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>1.09</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>1.37</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1px solid #bfbfbf;"><FONT STYLE="font-family:Verdana; "><B>1.26</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #bfbfbf;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1px solid #bfbfbf; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.70 &#8211; 1.40</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1.50pt solid #00b050;">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1.50pt solid #00b050;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:7pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:6pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Verdana" ALIGN="center"><B>Part 2 Only</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>&#8212;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>1.52</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;"><FONT STYLE="font-family:Verdana; "><B>0.69</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #00b050; BORDER-BOTTOM:1.50pt solid #00b050;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-BOTTOM:1.50pt solid #00b050;"><FONT STYLE="font-family:Verdana; "><B>0.95</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.50pt solid #00b050;">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:6pt ;BORDER-RIGHT:1.50pt solid #00b050; BORDER-BOTTOM:1.50pt solid #00b050; padding-right:2pt;"><FONT STYLE="font-family:Verdana; "><B>0.70 &#8211; 1.40</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Part 2 strengthened confidence in obefazimod&#8217;s benefit-risk profile ahead of NDA submission </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">The overall safety results observed in Part 2 were consistent with those previously observed in the broader obefazimod clinical development program. No new safety
pattern emerged with the additional cumulative exposure provided by Part 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Detailed exposure-adjusted analyses by trial, dose, cumulative patient-years, and
patient characteristics will be presented during today&#8217;s investor webcast. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Remo Pannacione, M.D., Professor of Medicine and Director of the IBD Clinic
at the University of Calgary</B><B><I> </I></B><B>stated</B><B><I>: </I></B><I>&#8220;The ABTECT Maintenance Trial delivered compelling evidence supporting the clinical potential of obefazimod in ulcerative colitis. The robust efficacy results
observed in both induction responders (Part 1) and induction <FONT STYLE="white-space:nowrap">non-responders</FONT> (Part 2) demonstrate a consistent treatment effect across clinically important patient populations, while the expanding long-term
safety dataset continues to provide reassurance, with observed rates of malignancies and <FONT STYLE="white-space:nowrap">non-melanoma</FONT> skin cancers remaining consistent with expected background rates in ulcerative colitis. Collectively, these
findings support a highly favorable benefit-risk profile and strengthen my confidence that obefazimod, if approved, has the potential to become an important new therapeutic option with the ability to meaningfully impact the treatment paradigm for
patients with ulcerative colitis.&#8221;</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Today&#8217;s Investor Webcast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Abivax management will host a webcast and conference call today at 4:30 p.m. EDT (10:30 p.m. CEST) to discuss the ABTECT Maintenance Part 2 results. To participate,
please use the following <FONT STYLE="white-space:nowrap">dial-in</FONT> or webcast link: <FONT STYLE="font-family:Verdana; font-size:11pt" COLOR="#467886"><U>https://edge.media-server.com/mmc/p/o5thz2vd</U></FONT><FONT STYLE="font-family:Verdana">
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Regulatory Path Forward </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">The ABTECT Maintenance Part 2
results expand the integrated clinical dataset supporting the planned New Drug Application (&#8220;NDA&#8221;) for obefazimod in UC. The Company remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of
2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Next Anticipated Key Milestones </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt">September&nbsp;21, 2026 &#8211; Half-year 2026 financial results </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt">Fourth Quarter 2026 &#8211; Planned NDA submission for obefazimod in UC </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt"><FONT STYLE="white-space:nowrap">Mid-2027</FONT> &#8211; Topline results from the Phase 2b
<FONT STYLE="white-space:nowrap">ENHANCE-CD</FONT> induction trial evaluating obefazimod in Crohn&#8217;s disease </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>UC Background Incidence
Rate Sources </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Verdana; " ALIGN="left">Long et al. <I>Gastroenterology</I>. 2012; Bencardino et al. <I>Cancers (Basel)</I>. 2025; Beaugerie et al. <I>The
Lancet</I>. 2009; Kaneko et al. <I>Journal of Clinical Medicine</I>. 2024, Lemaitre et al. <I>JAMA</I>. 2017, National Cancer Institute. <I>SEER Statistics</I>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Verdana; " ALIGN="left">Long et al. <I>Gastroenterology</I>. 2012; Bencardino et al. <I>Cancers (Basel)</I>. 2025; Abbas et al. <I>American
Journal of Gastroenterology</I>. 2014. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>About Abivax </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana" ALIGN="justify">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#8217;s natural regulatory mechanisms to
stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax&#8217;s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely
active ulcerative colitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Patrick Malloy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">SVP, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Abivax SA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><FONT STYLE="font-family:Verdana; font-size:11pt" COLOR="#0000ff"><U>patrick.malloy@abivax.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>LifeSci Communications </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Karissa Baltz, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana">Associate Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><FONT STYLE="font-family:Verdana; font-size:11pt" COLOR="#0000ff"><U>LSC_ABIVAX@lifescicomms.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g110874abivax.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Verdana"><B>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana"><I>This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company&#8217;s business. Words such as
&#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;on track,&#8221; &#8220;potential,&#8221; &#8220;will&#8221; and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking
statements include statements concerning the potential therapeutic benefit of obefazimod and obefazimod&#8217;s potential to redefine treatment expectations, the expected timing for completion of the Phase 2b
<FONT STYLE="white-space:nowrap">ENHANCE-CD</FONT> induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, the timing for reporting
Abivax&#8217;s half year 2026 financial results, and other statements that are not historical fact. Although Abivax&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and
developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company
with the French Autorit&eacute; des March&eacute;s Financiers pursuant to its legal obligations including its universal registration document (Document d&#8217;Enregistrement Universel) and in its Annual Report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended December&nbsp;31, 2025 filed with the U.S. Securities and Exchange Commission on March&nbsp;23, 2026 under the caption &#8220;Risk Factors.&#8221; These risks, contingencies and
uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug
candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company&#8217;s foreseeable and
unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and
IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press
release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company
becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for
information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and
should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own
judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves
about and to observe any such restrictions. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g110874abivax.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g110874abivax.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L /H# 1$  A$! Q$!_\0
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MT6.:*RF='6S0%6$;$$<5T8;-\PE6A%UY6;75]P/D_P#8# 'QCU< 8']DR_\
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M?PNTS2)XXUU64&YOW0YS*W;/HHPOX>]?G^>9C_:>-G6C\*T7HO\ /<9Z=7@
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M1TIGV8"" 0<@U^6#%H _/[_@H "?C5H.!_S H/\ TIN*_9^"_P#D7U/\;_\
M28DL^]]+_P"099_]<4_]!%?CE3XWZE%JLP"@#%\:_P#(FZ]_UX7'_HMJZL+_
M +Q3]5^8'PO^P("/C'J_!'_$IE_]&Q5^O\9_\BZ'^)?DR4?67[3W_) _&O\
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M(JC:M\H'W3Z/QP>_0U]SP]Q#++I+#XAWI/\ \E_X'D)GGG[+_P"U#=:#=Q^
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0*%55 P  .@%<3;D[O<#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
